A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Kidney International — Heerspink HJL, Cherney D, Postmus D, et al. | September 24, 2021
Treatment with dapagliflozin in patients with chronic kidney disease (CKD) and substantial albuminuria was shown to confer a reduction in the risk of abrupt declines in kidney function.
This is a pre-specified analysis of DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease, a randomized, double-blind, placebo-controlled trial with a median follow-up of 2.4 years).
Adults with CKD (urinary albumin-to-creatinine ratio 200–5000 mg/g and estimated glomerular filtration rate 25–75 mL/min/1.73m 2 ) were randomly assigned to dapagliflozin 10 mg/day matched to placebo (2152 persons each).
Serum creatinine doubling happened in 63 (2.9%) and 91 (4.2%) participants in the dapagliflozin and placebo groups, respectively (hazard ratio 0.68).
No heterogeneity was evident in the impact of dapagliflozin on abrupt reductions in renal function based on baseline subgroups.
In dapagliflozin and placebo groups, 52 (2.5%) and 69 (3.2%) participants suffered acute kidney injury-related serious adverse events, respectively (0.77).
Read the full article on Kidney International